RTP Mobile Logo
Oncology Grand Rounds Series: Part 1 — Cancer Immunotherapy
Released August 2016

Video excerpts from the first in a series of 8 integrated symposia held at the 2016 ONS Annual Congress. Featuring perspectives from Ms Marianne J Davies, Dr Roy S Herbst, Dr Evan J Lipson and Ms Virginia J Seery. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of cancer.

    OVERVIEW OF ACTIVITY
    The past several years have seen an explosion in the emergence of new potential therapies that leverage the natural ability of the human body to attack and treat cancer. Known as immune-mediated therapies, or cancer immunotherapies, these promising treatments are taking center stage at medical conferences and generating excitement all over the world. Of interest, “immunotherapies” are not new, as scientists have been investigating strategies to elicit an effective immune response against malignant tumors for more than a century and the first immune treatments in oncology received FDA approval in the 1990s. The newest and perhaps most exciting arena in cancer immunotherapy has been the development and assessment of immune-modulating antibodies, or checkpoint immune modulators. To date studies have demonstrated that these agents are highly active across a number of diseases, most notably melanoma, renal cell carcinoma, non-small cell lung cancer and bladder cancer, representing the dawn of a new era in oncologic treatment that may effectively transform chemotherapy infusion rooms into immunotherapy delivery centers.

    The introduction of these therapies has created a multitude of uncertainties, important clinical questions and knowledge gaps awaiting resolution. This seems to be particularly true among oncology nurses, who play an integral role in the successful delivery of systemic anticancer therapy and the preservation of patient physical and psychosocial well-being, thereby requiring that they possess a varied set of skills and an extensive knowledge base. These video proceedings from the first part of an 8-part integrated CNE curriculum originally held at the 2016 ONS Annual Congress feature discussions with leading oncology investigators and their nursing counterparts regarding actual patient cases and recent clinical research findings affecting the optimal therapeutic and supportive care for each patient scenario.

    PURPOSE STATEMENT
    By providing information on the latest research developments in the context of expert perspectives, this CNE activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of an understanding of the mechanism of action of cancer immunotherapies, their role in the clinical algorithm and the unique spectrum of associated side effects to facilitate optimal care of patients with cancer.

    LEARNING OBJECTIVES

    • Develop a basic understanding of the human immune response, and identify the underlying mechanisms by which various cancers evade this process to proliferate and grow.
    • Recognize the FDA approvals of nivolumab, pembrolizumab and the combination of nivolumab and ipilimumab for the management of metastatic melanoma, and understand where these approaches fit into the clinical algorithm.
    • Discuss the mechanism of action, clinical efficacy and tolerability profiles of checkpoint inhibitors and other immunotherapies in a variety of cancers.
    • Understand the broad spectrum of unique side effects related to immunotherapies, and develop a plan to monitor and care for patients accordingly.
    • Recall the design of ongoing clinical trials evaluating novel immunotherapeutic approaches, and counsel appropriately selected patients about availability and participation.

    ACCREDITATION STATEMENT

    CNE credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CNE credit is no longer available for this issue

    ONCC/ILNA CERTIFICATION INFORMATION
    The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

    CNE credit is no longer available for this issue

    FOR SUCCESSFUL COMPLETION
    This is a video CNE program.

    CNE credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME/CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Marianne J Davies, DNP, ACNP-BC, AOCNP-BC
    Assistant Professor
    Oncology Nurse Practitioner
    Yale Cancer Center
    New Haven, Connecticut

    Speakers Bureau: Bristol-Myers Squibb Company, Genentech BioOncology, Merck.

    Roy S Herbst, MD, PhD
    Ensign Professor of Medicine (Oncology)
    Professor of Pharmacology
    Chief of Medical Oncology
    Director, Thoracic Oncology Research Program
    Associate Director for Translational Research
    Yale Comprehensive Cancer Center
    Yale School of Medicine
    New Haven, Connecticut

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Biothera Pharmaceuticals, Bristol-Myers Squibb Company, Diatech, Genentech BioOncology, Kolltan Pharmaceuticals Inc, Lilly, Notl-microarrays; Consulting Agreements: Merck, Pfizer Inc.

    Evan J Lipson, MD
    Assistant Professor, Medical Oncology
    Melanoma and Cancer Immunology Programs
    Johns Hopkins University School of Medicine
    The Sidney Kimmel Comprehensive Cancer Center
    Baltimore, Maryland

    Advisory Committee: Amgen Inc, Castle Biosciences Incorporated; Consulting Agreements: Bristol-Myers Squibb Company, Merck.

    Virginia J Seery, MSN, RN, ANP-BC
    Nurse Practitioner, Cutaneous Oncology and Biologics Program
    Beth Israel Deaconess Medical Center
    Boston, Massachusetts

    No relevant conflicts of interest to disclose.

    MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME/CNE activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology and Merck.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: August 2016
    Expiration date: August 2017

    There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):
Video segments: